SNAPSHOT2 min read

Why China’s stunning vaccine surge could be good news for the world

The extraordinary recent pace of China’s vaccine roll out could be good news for other emerging markets.



David Rees
Senior Emerging Markets Economist

Not only is the rapid roll-out of Covid-19 vaccinations in China good news for the domestic economy, but it could also potentially see a sharp increase in exports of treatments to other emerging markets (EM).

That would help those EM that have so far lagged behind in the vaccination race. And the geopolitical dynamics could also see the G7 boost its own targets for delivering vaccines to the emerging world.

The pace of vaccinations in China has accelerated sharply

China is now rolling out Covid-19 vaccines at a blistering pace. According to the National Health Commission, the total number of vaccines delivered broke through the 1 billion barrier over the weekend.

About two thirds of the 1.4 billion population has received at least one dose, and the government aims to have fully vaccinated 40% of the population by July.


It will be difficult for the authorities to sustain this rapid rate of inoculations, which has seen it deliver roughly 20 million shots per day in the past week, as the roll-out moves into less urban areas.

But it seems that the government is on track to meets its previous official target to vaccinate 80% of the population by the end of the year much more quickly than anticipated. Indeed, at current rates the target could be met at some point during the third quarter.

That should be good news for China.

Could this provide a modest boost to domestic consumption?

The rapid roll-out of vaccines should ease concerns about low levels of natural immunity in China. The government’s robust handling of Covid through strict lockdowns last year virtually eradicated new, domestically transmitted cases of the virus within two months of the outbreak being officially reported.

But it also meant that China built up very little natural immunity. As has been seen in other countries around the world that have handled Covid through containment, this has left populations and economies vulnerable to fresh outbreaks particularly of new, more infectious variants.

Meanwhile, the faster roll-out of vaccinations may give some marginal support to the recovery in consumer spending, which has so far lagged behind the broader economic rebound. Relatively sluggish consumer activity probably reflects some structural shift in economic activity, for example in remote working, along with an apparent absence of a strong recovery in the labour market. But to the extent that hesitancy regarding Covid has been a headwind for consumption, this should fade as the vaccination rate climbs.

Why this is also good news for broader emerging markets

China’s vaccine boom should also be good news for the rest of the world. The implication of China meeting its domestic vaccination targets more quickly than anticipated is that it might not be long before it begins to export large numbers of shots to other EM that have so far been starved of reliable supply.

As we noted earlier this year, both China and Russia were likely to try and fill the vaccine vacuum in EM caused in large part by hoarding in developed markets. China in particular had at the time already agreed to supply its home-grown vaccines to most countries in Africa and Latin America along with parts of Asia and Europe.


Concerns about vaccine diplomacy could also see other countries respond by offering more shots to EM. The US announced last month that it would prioritise sending vaccines to parts of Latin America after China provided deliveries of inoculations to countries in the region. G7 leaders announced at the end of their recent meeting in the UK plans to donate 1 billion vaccines over the next year, but could feel compelled to be more ambitious if China does start to ramp-up its exports.

Anything that can speed-up the roll-out of vaccines in EM would clearly be good news for dealing with the global pandemic and slowing the emergence of new variants. And better handling the health crisis could also have some positive spill over to the economic outlook and performance of assets in the emerging world.

The views and opinions contained herein are those of Schroders’ investment teams and/or Economics Group, and do not necessarily represent Schroder Investment Management North America Inc.’s house views. These views are subject to change. This information is intended to be for information purposes only and it is not intended as promotional material in any respect.


David Rees
Senior Emerging Markets Economist


Fixed Income
David Rees
Emerging Markets
Asia ex Japan

Please consider a fund's investment objectives, risks, charges and expenses carefully before investing. The Schroder mutual funds (the “Funds”) are distributed by The Hartford Funds, a member of FINRA. To obtain product risk and other information on any Schroders Fund, please click the following link. Read the prospectus carefully before investing. To obtain any further information call your financial advisor or call The Hartford Funds at 1-800-456-7526 for Individual Investors.  The Hartford Funds is not an affiliate of Schroders plc.

Schroder Investment Management North America Inc. (“SIMNA”) is an SEC registered investment adviser, CRD Number 105820, providing asset management products and services to clients in the US and registered as a Portfolio Manager with the securities regulatory authorities in Canada.  Schroder Fund Advisors LLC (“SFA”) is a wholly-owned subsidiary of SIMNA Inc. and is registered as a limited purpose broker-dealer with FINRA and as an Exempt Market Dealer with the securities regulatory authorities in Canada.  SFA markets certain investment vehicles for which other Schroders entities are investment advisers.”

For illustrative purposes only and does not constitute a recommendation to invest in the above-mentioned security/sector/country.

Schroders Capital is the private markets investment division of Schroders plc. Schroders Capital Management (US) Inc. (‘Schroders Capital US’) is registered as an investment adviser with the US Securities and Exchange Commission (SEC).It provides asset management products and services to clients in the United States and Canada.For more information, visit

SIMNA, SFA and Schroders Capital are wholly owned subsidiaries of Schroders plc.